The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.
The NCPE recommends reimbursement of alemtuzumab (Lemtrada®).
The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.
The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib.
The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.
The NCPE does not consider Suboxone® to be cost-effective compared to methadone for the treatment of opioid dependence.
The NCPE does not recommend reimbursement of teriflunomide
(Aubagio®) at the current price.
The NCPE believe that, at the submitted price, brentuximab is not cost effective for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin Lymphoma who have failed at least one autologous stem cell transplant
The NCPE believe that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel
The NCPE consider this to be a cost effective product for the defined patient population in combination with psychosocial intervention.